Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q4 2025
Biocryst Pharmaceuticals (BCRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Biocryst Pharmaceuticals (BCRX) reported revenue of $407M for the fourth quarter 2025 (Q4 2025), +209% from a year earlier and +155% from the quarter before. Operating margin was 64.0%, net earnings $246M (60.5% of revenue).
Biocryst Pharmaceuticals, Q4 2025: revenue $407M (+209% year over year), operating margin 64.0%, net earnings $246M, operating cash flow $292M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $407M | +155% | +209% |
| Operating profit | $260M | +780% | — |
| Net earnings | $246M | 19× | — |
| Operating cash flow | $292M | +601% | — |
| Free cash flow | $291M | +623% | — |
What changed
Revenue was $406.6M in Q4 2025, up 209% year over year and up 155% from the previous quarter.
Operating profit was $260.4M, a 64.0% margin (up 67.5 points year over year). Total costs grew 7% against revenue growth of 209%. The fastest-growing cost line was Cost of revenue (+56%). Net earnings were $245.8M. The effective tax rate was 0.9%.
Operating cash flow was $292.0M, 119% of net earnings. Non-cash charges added back $394K of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items added $21.9M. Capital expenditures of $802K left free cash flow of $291.2M.
Questions
What was Biocryst Pharmaceuticals' revenue in the fourth quarter 2025?
Biocryst Pharmaceuticals (BCRX) reported revenue of $407M for the fourth quarter 2025 (Q4 2025), +209% from a year earlier and +155% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $260M (64.0% of revenue) and net earnings $246M.